Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the first quarter of the fiscal year 2024, concluded on December 31, 2023. On a currency-adjusted basis, sales increased by 5.7% to EUR 5.18 billion (USD 5.6 billion). When excluding the impact of COVID-19-related sales, the growth rate reached 7.0%.
Breaking down the figures by business unit, Imaging sales saw a year-on-year (YOY) increase of 5.3% to EUR 2.79 billion (USD 3.01 billion). Diagnostics experienced a YOY decrease of 4% to EUR 1.06 billion (USD 1.14 billion). Varian, the company’s radiation oncology unit, grew by 22.3% to EUR 911 million (USD 982 million). Advanced Therapies also reported a YOY increase of 5% to EUR 475 million (USD 512 million).
Regionally, the EMEA region and China were the main drivers of growth, with China’s performance attributed to a comparison with the pandemic-weakened prior-year quarter. The Americas region recorded moderate revenue growth, while the Asia-Pacific Japan region exhibited a moderate decline, primarily due to the loss of COVID diagnostic revenues.- Flcube.com
